TY  - JOUR
AU  - Sartor, Oliver
AU  - Heinrich, Daniel
AU  - Mariados, Neil
AU  - Mendez Vidal, Maria Jose
AU  - Keizman, Daniel
AU  - Thellenberg Karlsson, Camilla
AU  - Peer, Avivit
AU  - Procopio, Giuseppe
AU  - Frank, Stephen J
AU  - Pulkkanen, Kalevi
AU  - Rosenbaum, Eli
AU  - Severi, Stefano
AU  - Trigo, Jose
AU  - Trandafir, Lucia
AU  - Wagner, Volker
AU  - Li, Rui
AU  - Nordquist, Luke T
PY  - 2019
DO  - 10.1002/pros.23893
UR  - http://hdl.handle.net/10668/14435
T2  - The Prostate
AB  - Radium-223 dichloride (radium-223) is approved for patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no visceral disease using a dosing regimen of 6 injections (55 kBq/kg intravenously; 1 injection every 4...
LA  - en
PB  - Wiley
KW  - SSEs
KW  - Alkaline phosphatase
KW  - Prostate-specific antigen
KW  - Safety
KW  - Survival
KW  - Symptomatic skeletal events
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic agents
KW  - Bone neoplasms
KW  - Disease progression
KW  - Follow-up studies
KW  - Humans
KW  - Male
KW  - Middle aged
KW  - Prostate-specific antigen
KW  - Prostatic neoplasms, castration-resistant
KW  - Radioisotopes
KW  - Radium
KW  - Survival rate
TI  - Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
TY  - research article
VL  - 79
ER  -